In this study we evaluated the percentages of CD3(-)CD56(bright), CD3(-)CD56(dim), CD3(-)CD56(bright)perforin(+) and CD3(-)CD56(dim)perforin(+) Natural Killer (NK) cells in peripheral blood from untreated secondary progressive (SP) and primary progressive (PP) multiple sclerosis (MS) patients and age and sex matched healthy subjects. Both PPMS patients and SPMS patients showed increased percentages of circulating CD3(-)CD56(dim)perforin(+) NK cells than healthy subjects. The increased percentage of CD3(-)CD56(dim) NK cells expressing perforin in patients affected by the progressive forms of MS suggests a possible role of this NK cell subpopulation in the pathogenesis of the disease
Immunological profile of multiple sclerosis patients Abstrakt Multiple sclerosis is an autoimmune ne...
<p>A) NK cells were isolated from the blood of MS patients. CD56<sup>+</sup> cells were isolated and...
Funding. This work was supported by the EU FP7-MINECO Infect-ERA Program (PCIN-2015-191-C02-01), and...
In this study we evaluated the percentages of CD3(-)CD56(bright), CD3(-)CD56(dim), CD3(-)CD56(bright...
Relapsing-remitting multiple sclerosis (RRMS), secondary progressive (SP)MS and primary progressive ...
Relapsing-remitting multiple sclerosis (RRMS), secondary progressive (SP)MS and primary progressive ...
Multiple sclerosis (MS), is a chronic inflammatory disease of central nervous system with unclear et...
This thesis addresses the hypothesis that multiple sclerosis (MS) patients have an imbalance in the ...
Background Multiple sclerosis (MS) is an autoimmune inflammatory disease of the central nervous syst...
The importance of circulating immune cells to primary progressive multiple sclerosis (PPMS) pathophy...
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) characterized b...
Background: Previous studies have reported impaired cytotoxic activity in Natural Killer (NK) CD56Di...
Background: Multiple sclerosis (MS) and Neuromyelitis optica (NMO) are inflammatory and demyelinatin...
NK cells are multicompetent lymphocytes of the innate immune system with a central role in host defe...
Recent evidence has shown that CD56bright NK cells, a subset of NK cells abundant in lymph nodes, ma...
Immunological profile of multiple sclerosis patients Abstrakt Multiple sclerosis is an autoimmune ne...
<p>A) NK cells were isolated from the blood of MS patients. CD56<sup>+</sup> cells were isolated and...
Funding. This work was supported by the EU FP7-MINECO Infect-ERA Program (PCIN-2015-191-C02-01), and...
In this study we evaluated the percentages of CD3(-)CD56(bright), CD3(-)CD56(dim), CD3(-)CD56(bright...
Relapsing-remitting multiple sclerosis (RRMS), secondary progressive (SP)MS and primary progressive ...
Relapsing-remitting multiple sclerosis (RRMS), secondary progressive (SP)MS and primary progressive ...
Multiple sclerosis (MS), is a chronic inflammatory disease of central nervous system with unclear et...
This thesis addresses the hypothesis that multiple sclerosis (MS) patients have an imbalance in the ...
Background Multiple sclerosis (MS) is an autoimmune inflammatory disease of the central nervous syst...
The importance of circulating immune cells to primary progressive multiple sclerosis (PPMS) pathophy...
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) characterized b...
Background: Previous studies have reported impaired cytotoxic activity in Natural Killer (NK) CD56Di...
Background: Multiple sclerosis (MS) and Neuromyelitis optica (NMO) are inflammatory and demyelinatin...
NK cells are multicompetent lymphocytes of the innate immune system with a central role in host defe...
Recent evidence has shown that CD56bright NK cells, a subset of NK cells abundant in lymph nodes, ma...
Immunological profile of multiple sclerosis patients Abstrakt Multiple sclerosis is an autoimmune ne...
<p>A) NK cells were isolated from the blood of MS patients. CD56<sup>+</sup> cells were isolated and...
Funding. This work was supported by the EU FP7-MINECO Infect-ERA Program (PCIN-2015-191-C02-01), and...